



GENFIT EXTENDS PATENT PROTECTION ON GFT505 IN MAJOR WORLDWIDE COUNTRIES

Lille (France), Cambridge (Massachusetts, United States), January 8, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, announced today that the company has extended the patent protection in major worldwide pharmaceutical markets on GFT505, the most advanced drug candidate of the company for which important achievements in clinical development have been recently announced.

In addition to those already granted in previous years, patents have been recently issued by the patent offices in USA, Europe, China, Russia, and Australia, amongst others. Taken together, these patents grant GENFIT an extensive protection of the exclusivity for a complete range of subject matters related to GFT505, including a large series of structural variants, pharmaceutical uses and compositions in the field of cardiometabolic diseases, process of production, and pharmaceutical combinations.

The patent protection covers the uses of GFT505, which is in keeping with the recently obtained clinical results demonstrating the efficacy of GFT505 in atherogenic dyslipidemia patients, and provide an expected improved safety profile with respect to competitor drugs.

Jean-François Mouney, CEO of GENFIT commented: “GENFIT has created a GFT505 package that is solid and competitive in terms of both clinical evidence and of exclusive patent coverage. Moreover, the company is pursuing further technological and clinical development activities that will lead to additional patent filings in 2010 that will further strengthen GENFIT’s strategic position”.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer’s...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT’s proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS (AVE0897) and SOLVAY (SLV341), are in the advanced stages of Phase I.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has about 130 employees, including over 100 scientists. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board

+33 (0)3 20 16 40 00

MILESTONES – Press Relations

Bruno Arabian

+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.